Cartesian Therapeutics (RNAC) Stock Price
Cartesian Therapeutics Price
Revenue at Cartesian Therapeutics has contracted by 0.8% per year over the past 11 years to 2.80 M USD. Cartesian Therapeutics's net margin stands at -4,658.6%, down from -30.2% several years earlier. Analysts set a median price target of 20.50 USD, implying 206.9% above the current price. Of 14 analysts, 13 rate the stock a buy — an overall Buy consensus.
Cartesian Therapeutics stock price
Cartesian Therapeutics business model & stock analysis
Frequently asked questions about Cartesian Therapeutics
Analysts currently set an average price target of 20.50 USD for the Cartesian Therapeutics stock (median: 20.50 USD), implying +206.9 % versus the latest price. The consensus is based on 14 analyst ratings.
14 analysts currently rate the Cartesian Therapeutics stock: 13 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Cartesian Therapeutics to generate revenue of 422,286.00 USD and earnings per share of -3.01 USD.
Converted at the current exchange rate, the Cartesian Therapeutics share trades at 5.96 EUR (6.68 USD).
The Cartesian Therapeutics share (RNAC) is listed on 3 stock exchanges, including: NASDAQ (SELB), Frankfurt (1S7.F), München (1S7.MU).
The expected revenue of Cartesian Therapeutics is 422,286.00 USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Cartesian Therapeutics is -78.09 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Cartesian Therapeutics is currently -2.22. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Cartesian Therapeutics stock.
The price-to-sales ratio (P/S) of Cartesian Therapeutics is currently 410.86. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Cartesian Therapeutics stock.
The Eulerpool Quality Score for Cartesian Therapeutics is 1/10.
The ISIN of Cartesian Therapeutics is US8162123025. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Cartesian Therapeutics is A2AML0. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Cartesian Therapeutics is RNAC. The ticker symbol is used to trade Cartesian Therapeutics shares on the stock exchange.
Cartesian Therapeutics stock
Cartesian Therapeutics Peer Group
Cartesian Therapeutics Ticker
All fundamentals and in-depth analysis of Cartesian Therapeutics
Our stock analysis for Cartesian Therapeutics stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Cartesian Therapeutics. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.